Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Leukemia · 2024-12 · 38 (12) · 2517-2543
DOI: 10.1038/s41375-024-02444-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Leukemia, online erschienen am 25.10.2024. Verfasst von Tao Lei und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510145, China. Hauptthemen laut MEDLINE: Gene Editing, Immunotherapy, Adoptive, CRISPR-Cas Systems, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 139-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune therapy. However, challenges remain including increasing efficacy, reducing adverse events and increasing accessibility. Use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology can effectively perform various functions such as precise integration, multi-gene editing, and genome-wide functional regulation. Additionally, CRISPR screening using large-scale guide RNA (gRNA) genetic perturbation provides an unbiased approach to understanding mechanisms underlying anti-cancer efficacy of CAR T-cells. Several emerging CRISPR tools with high specificity, controllability and efficiency are useful to modify CAR T-cells and identify new targets. In this review we summarize potential uses of the CRISPR system to improve results of CAR T-cells therapy including optimizing efficacy and safety and, developing universal CAR T-cells. We discuss challenges facing CRISPR gene editing and propose solutions highlighting future research directions in CAR T-cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510145, China.
- School of Life Sciences, Tsinghua University, Beijing, 100084, China.
- The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510145, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. xuxinjiepumc@126…
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK. robertpeter@alumni.ucla.edu.
ORCID-Profile: Xinjie Xu, Liang Wang
Zitieren
APA
Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., Wang, L., Xu, X., Gale, R. P., & Wang, L. (2024). Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia, 38(12), 2517-2543. https://doi.org/10.1038/s41375-024-02444-y
Vancouver
Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38(12):2517-2543. doi:10.1038/s41375-024-02444-y
BibTeX
@article{Lei2024,
author = {Lei, Tao and Wang, Yazhuo and Zhang, Yuchen and Yang, Yufei and Cao, Jiaying and Huang, Jiansong and Chen, Jiali and Chen, Huajing and Zhang, Jiayi and Wang, Luzheng and Xu, Xinjie and Gale, Robert Peter and Wang, Liang},
title = {Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy},
journal = {Leukemia},
year = {2024},
volume = {38},
number = {12},
pages = {2517--2543},
doi = {10.1038/s41375-024-02444-y}
}
EUVIMED